Basit öğe kaydını göster

dc.contributor.authorBayraktar, Zeki
dc.contributor.authorAlbayrak, Selami
dc.date.accessioned2020-03-12T08:24:27Z
dc.date.available2020-03-12T08:24:27Z
dc.date.issued2017en_US
dc.identifier.citationBayraktar, Z. ve Albayrak, S. (2017). Metastasis of renal cell carcinoma to the thyroid gland 9 years after nephrectomy: A case report and literature review. Archivio Italiano di Urologia e Andrologia, 89(2), 151-153. http://doi.org/10.4081/aiua.2017.2.151en_US
dc.identifier.issn1124-3562
dc.identifier.ismn2282-4197
dc.identifier.urihttp://doi.org/10.4081/aiua.2017.2.151
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5031
dc.description.abstractWe report a case presenting with thyroid and lung metastases of renal cell carcinoma that was treated with molecular targeted therapy followed metastasectomy. A 52-year-old female underwent radical nephrectomy of right renal cell carcinoma in 2007. The patient presented 9 years after nephrectomy at the age of 61 years with sudden loss of vision on the left side and a mass on the neck. On magnetic resonance imagining, there was a mass on the midline of the neck, extending to the left, measuring 46 x 31 mm and containing central cystic-necrotic areas. Fine-needle aspiration biopsy was performed. The histopathological examination of the biopsy specimen revealed a lesion composed of malignant epithelial cells compatible with metastasis of renal carcinoma. Computed tomography showed multiple metastases in bilateral lungs. Metastasectomy and total tiroidectomy were performed. Thyroid and lung metastasis of renal cell carcinoma were pathologically confirmed. But on the first computed tomography after metastasectomy, there was residual tumor in the thyroid. Interferon-alpha therapy was given for 8 weeks. After that, pazopanib therapy started. Three months later, on computed tomography, residual metastatic foci were regressed. The patient was followed up for 1 year after metastasectomy. The patient is currently receiving a single dose of pazopanib per day ( 400 mg/day) and the general condition is good. Thyroid metastasis should be considered in patients with a thyroid nodule and positive history for renal cell carcinoma. Successful results can be obtained with metastasectomy and systemic targeted therapy.en_US
dc.language.isoengen_US
dc.publisherPagePress Publicationsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectMetastasisen_US
dc.subjectThyroiden_US
dc.subjectMetastasectomyen_US
dc.subjectTargeted Therapyen_US
dc.titleMetastasis of renal cell carcinoma to the thyroid gland 9 years after nephrectomy: A case report and literature reviewen_US
dc.typereviewen_US
dc.relation.ispartofArchivio Italiano di Urologia e Andrologiaen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.authorid0000-0002-2493-2457en_US
dc.authorid0000-0002-4245-7506en_US
dc.identifier.volume89en_US
dc.identifier.issue2en_US
dc.identifier.startpage151en_US
dc.identifier.endpage153en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.4081/aiua.2017.2.151en_US
dc.identifier.scopusqualityQ3en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster